Accepted for Publication: May 12, 2021.
Published: July 23, 2021. doi:10.1001/jamanetworkopen.2021.18223
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2021 Joudrey PJ et al. JAMA Network Open.
Corresponding Author: Paul J. Joudrey, MD, MPH, Department of Internal Medicine, Yale School of Medicine, 367 Cedar St, Harkness Hall A, New Haven, CT 06520 (email@example.com).
Author Contributions: Dr Joudrey had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Drs Edelman and Wang are co–senior authors.
Concept and design: Joudrey, Bach, Kimmel, Sung, You Kheang, E. Wang, Edelman.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Joudrey, Guerra, Medley, Sung, You Kheang, E. Wang.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Joudrey, Chaiton, Kimmel, Medley, Zhang.
Obtained funding: Joudrey.
Administrative, technical, or material support: Adams, Van Buren, Chaiton, Ehrenfeld, Guerra, Medley, You Kheang, Zhang.
Supervision: Bach, E. Wang, Edelman.
Conflict of Interest Disclosures: Dr Bach reported grants from the Michael Smith Foundation for Health Research and grants from the Canadian Institutes of Health Research outside the submitted work. Dr Kimmel reported personal fees from Abt Associates for work as a consultant on access to medications for opioid use disorder in nursing facilities and personal fees from the American Academy of Addiction Psychiatry Fees for lecturing about medications for opioid use disorder and harm reduction as part of the opioid response network outside the submitted work. No other disclosures were reported.
Funding/Support: Funding for this publication was provided by grant number 5K12DA033312 (Dr Joudrey), L30 DA052056 (Dr Joudrey), and 1UM1DA049412-01 (Dr Kimmel) from the National Institute on Drug Abuse, a component of the National Institutes of Health.
Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Meeting Presentation: Data from this work was presented during the College on the Problems of Drug Dependence COVID-19 Impacts on SUD Research Webinar; October 29, 2020.
Additional Contributions: We thank Kim Jiang for her completion of standardized patient calls for this project. She was not compensated.
MR , Bernson
D , Land
et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study. Ann Intern Med
. 2018;169(3):137-145. doi:10.7326/M17-3107PubMedGoogle ScholarCrossref
QQ , Kaelber
DC , Xu
R , Volkow
ND . COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States. Mol Psychiatry
. Published online September 14, 2020:1-10. doi:10.1038/s41380-020-00880-7Google Scholar
AI , Mancher
M . Medications for Opioid Use Disorder Save Lives. National Academies of Sciences, Enginneering, and Medicine; 2019.
KM , Darnton
J , Grekin
et al. Rapid implementation of service delivery changes to mitigate COVID-19 and maintain access to methadone among persons with and at high-risk for HIV in an opioid treatment program. AIDS Behav
. 2020;24(9):2469-2472. doi:10.1007/s10461-020-02887-1PubMedGoogle ScholarCrossref
T , Saloner
B , Wakeman
SE , Gaye
M , Barnett
ML . Access to office-based buprenorphine treatment in areas with high rates of opioid-related mortality: an audit study. Ann Intern Med
. 2019;171(1):1-9. doi:10.7326/M18-3457PubMedGoogle ScholarCrossref
MI , King
VL , Brooner
RK , Rastegar
DA . A comparison of characteristics and outcomes of opioid-dependent patients initiating office-based buprenorphine or methadone maintenance treatment. Subst Abus
. 2014;35(2):122-126. doi:10.1080/08897077.2013.819828PubMedGoogle ScholarCrossref
AS , Strain
EC , Jardot
et al. Treatment Disruption and Childcare Responsibility as Risk Factors for Drug and Alcohol Use in Persons in Treatment for Substance Use Disorders During the COVID-19 Crisis. J Addict Med
. 2021. doi:10.1097/ADM.0000000000000813PubMedGoogle Scholar
AJ , Andrews
CM , Yingling
ME , Shannon
J . Geographic disparities in availability of opioid use disorder treatment for Medicaid enrollees. Health Serv Res
. 2018;53(1):389-404. doi:10.1111/1475-6773.12686PubMedGoogle Scholar
JK , Gomes
T , Martins
et al. Evaluating the effectiveness of first-time methadone maintenance therapy across northern, rural, and urban regions of Ontario, Canada. J Addict Med
. 2015;9(6):440-446. doi:10.1097/ADM.0000000000000156PubMedGoogle Scholar
G , Torres-Lockhart
K , Stein
MR , Mund
P , Nahvi
S . Reimagining patient-centered care in opioid treatment programs: lessons from the Bronx during COVID-19. J Subst Abuse Treat
. Published online December 3, 2020:108219. doi:10.1016/j.jsat.2020.108219
S , Joudrey
PJ , Wang
EA , Thornhill
IV , Gonsalves
G . Expanding access to methadone treatment in Ohio through federally qualified health centers and a chain pharmacy: a geospatial modeling analysis. Drug Alcohol Depend
. 2021;220:108534. doi:10.1016/j.drugalcdep.2021.108534PubMedGoogle Scholar
P , Jacob
B , Zaheer
J , Fischer
B . Patterns of methadone maintenance treatment provision in Ontario: policy success or pendulum excess? Can Fam Physician
. 2018;64(2):e95-e103.PubMedGoogle Scholar